30 results
POS AM
LSB
LakeShore Biopharma Co., Ltd
23 Jan 24
Prospectus update (post-effective amendment)
4:18pm
and beliefs concerning future developments and their potential effects on YS Biopharma. There can be no assurance that future developments affecting YS … be no assurance that any of YS Group’s technology, marketed product or product candidates will be protectable or remain protected by valid and enforceable
424B3
LSB
LakeShore Biopharma Co., Ltd
15 Aug 23
Prospectus supplement
8:00am
Biopharma. There can be no assurance that future developments affecting YS Biopharma will be those that YS Biopharma has anticipated. These forward-looking … Group’s patent rights are highly uncertain, and there can be no assurance that any of YS Group’s technology, marketed product or product candidates
POS AM
v1dxz sdp
8 Aug 23
Prospectus update (post-effective amendment)
4:06pm
20-F
emycf
26 Jul 23
Annual report (foreign)
4:02pm
20-F
EX-12.1
x38stkcbw
26 Jul 23
Annual report (foreign)
4:02pm
20-F
EX-12.2
3zvxx
26 Jul 23
Annual report (foreign)
4:02pm
424B3
6wt993jqgbmeec5
5 Jun 23
Prospectus supplement
4:03pm
F-1/A
nozot3vgthctm
12 May 23
Registration statement (foreign) (amended)
4:05pm
CORRESP
ry41zje8r6dcyns7en
12 May 23
Correspondence with SEC
12:00am
6-K
EX-99.1
b51f99wpogrx pr3cw
18 Apr 23
YS Biopharma Announces Record Vaccine Revenues and Preliminary
8:00am
F-1
o221t27
12 Apr 23
Registration statement (foreign)
8:49am
F-4
EX-10.6
jv22nt 4pfvsdj6
28 Dec 22
Registration of securities (foreign)
6:58am
F-4
EX-10.10
29f7d83
28 Dec 22
Registration of securities (foreign)
6:58am
F-4
87vex50
28 Dec 22
Registration of securities (foreign)
6:58am
F-4
EX-10.9
8dq 5ja67pcqv4y35
28 Dec 22
Registration of securities (foreign)
6:58am
F-4
EX-99.3
n9lbjkoytb i6
28 Dec 22
Registration of securities (foreign)
6:58am
CORRESP
simzuuvc
28 Dec 22
Correspondence with SEC
12:00am